View Filing Data

Print Document View Excel Document

Document and Entity Information	6 Months Ended
Document and Entity Information	Apr. 30, 2017 shares
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Entity Registrant Name	COOPER COMPANIES INC
Entity Central Index Key	0000711404
Current Fiscal Year End Date	--10-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	48,856,777

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Income Statement [Abstract]
Net sales	$ 522,400	$ 483,800	$ 1,021,500	$ 933,400
Cost of sales	178,500	185,300	365,300	372,900
Gross profit	343,900	298,500	656,200	560,500
Selling, general and administrative expense	193,300	177,700	381,900	351,300
Research and development expense	16,800	16,700	33,100	31,500
Amortization of intangibles	16,700	14,300	33,400	30,500
Operating income	117,100	89,800	207,800	147,200
Interest expense	7,700	7,600	15,000	12,900
Other (income) expense, net	(100)	(400)	3,200	900
Income before income taxes	109,500	82,600	189,600	133,400
Provision for income taxes	4,600	8,200	8,900	7,200
Net income	104,900	74,400	180,700	126,200
Less: net income attributable to noncontrolling interests	0	300	0	700
Net income attributable to Cooper stockholders	$ 104,900	$ 74,100	$ 180,700	$ 125,500
Earnings per share attributable to Cooper stockholders - basic (in dollars per share)	$ 2.14	$ 1.53	$ 3.70	$ 2.59
Earnings per share attributable to Cooper stockholders - diluted (in dollars per share)	$ 2.12	$ 1.52	$ 3.65	$ 2.57
Number of shares used to compute earnings per share:
Basic (shares)	48,959	48,400	48,900	48,400
Diluted (shares)	49,499	48,853	49,500	48,800

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 104,900	$ 74,400	$ 180,700	$ 126,200
Other comprehensive income (loss):
Foreign currency translation adjustment	38,300	52,300	66,500	(61,500)
Comprehensive income	143,200	126,700	247,200	64,700
Less: comprehensive income attributable to noncontrolling interests	0	700	0	700
Comprehensive income attributable to Cooper stockholders	$ 143,200	$ 126,000	$ 247,200	$ 64,000

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Current assets:
Cash and cash equivalents	$ 121.3	$ 100.8
Trade accounts receivable, net of allowance for doubtful accounts of $9.4 at April 30, 2017 and $8.5 at October 31, 2016	311.2	291.4
Inventories	437.6	417.7
Deferred tax assets (1)	0.0	49.7
Prepaid expense and other current assets	88.2	77.5
Total current assets	958.3	937.1
Property, plant and equipment, at cost	1,675.2	1,603.2
Less: accumulated depreciation and amortization	788.7	725.5
Property, plant and equipment, net	886.5	877.7
Goodwill	2,302.7	2,164.7
Other intangibles, net	485.0	441.1
Deferred tax assets (1)	59.7	6.1
Other assets	57.6	51.9
Total assets	4,749.8	4,478.6
Current liabilities:
Short-term debt	41.3	226.3
Accounts payable	100.4	107.4
Employee compensation and benefits	62.5	77.7
Other current liabilities	139.0	131.8
Total current liabilities	343.2	543.2
Long-term debt	1,345.6	1,107.4
Deferred tax liabilities (1)	25.6	37.5
Accrued pension liability and other	95.6	94.6
Total liabilities	1,810.0	1,782.7
Commitments and contingencies
Stockholders’ equity:
Preferred stock, 10 cents par value, shares authorized: 1.0; zero shares issued or outstanding	0.0	0.0
Common stock, 10 cents par value, shares authorized: 120.0; issued 52.3 at April 30, 2017 and 52.1 at October 31, 2016	5.2	5.2
Additional paid-in capital	1,503.8	1,494.0
Accumulated other comprehensive loss	(423.1)	(489.6)
Retained earnings	2,243.4	2,046.3
Treasury stock at cost: 3.4 shares at April 30, 2017 and 3.3 shares at October 31, 2016	(389.7)	(360.1)
Noncontrolling interests	0.2	0.1
Stockholders’ equity	2,939.8	2,695.9
Total liabilities and stockholders' equity	$ 4,749.8	$ 4,478.6

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for doubtful accounts	$ 9.4	$ 8.5
Preferred stock, par value	$ 0.1	$ 0.1
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.1	$ 0.1
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	52,300,000	52,100,000
Treasury stock, shares	3,400,000	3,300,000

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Cash flows from operating activities:
Net income	$ 180,700	$ 126,200
Depreciation and amortization	94,000	101,400
Decrease in operating capital	(59,500)	(61,600)
Other non-cash items	24,900	21,400
Net cash provided by operating activities	240,100	187,400
Cash flows from investing activities:
Purchases of property, plant and equipment	(57,300)	(86,300)
Acquisitions of businesses, net of cash acquired, and other	(173,800)	(145,500)
Net cash used in investing activities	(231,100)	(231,800)
Cash flows from financing activities:
Proceeds from long-term debt	619,000	1,367,300
Repayments of long-term debt	(374,000)	(1,250,400)
Net repayments of short-term debt	(192,400)	(23,600)
Repurchase of common stock	(29,500)	0
Net payments related to share-based compensation awards	(10,000)	(11,400)
Excess tax benefit from share-based compensation awards	0	5,000
Dividends on common stock	(1,500)	(1,500)
Debt acquisition costs	0	12,500
Distributions to noncontrolling interests	0	400
Payment of contingent consideration	(3,700)	0
Proceeds from construction allowance	2,100	0
Net cash provided by financing activities	10,000	72,500
Effect of exchange rate changes on cash and cash equivalents	1,500	0
Net increase in cash and cash equivalents	20,500	28,100
Cash and cash equivalents - beginning of period	100,800	16,400
Cash and cash equivalents - end of period	$ 121,300	$ 44,500

General

6 Months Ended

Apr. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

General

The Cooper Companies, Inc. (Cooper, we or the Company) is a global medical device company publicly traded on the NYSE Euronext (NYSE: COO). Cooper is dedicated to being A Quality of Life Company^TM with a focus on delivering shareholder value. Cooper operates through our business units, CooperVision and CooperSurgical.


•	CooperVision primarily develops, manufactures and markets a broad range of soft contact lenses for the worldwide vision correction market.


•	CooperSurgical primarily develops, manufactures, markets medical devices and procedures solutions, and provides services to improve health care delivery to families.

The unaudited consolidated condensed financial statements presented in this report contain all adjustments necessary to present fairly Cooper’s consolidated condensed financial position at April 30, 2017 and October 31, 2016, the consolidated results of its operations for the three and six months ended April 30, 2017 and 2016 and its consolidated condensed cash flows for the six months ended April 30, 2017 and 2016. Most of these adjustments are normal and recurring. However, certain adjustments associated with acquisitions are of a nonrecurring nature. Readers should not assume that the results reported here either indicate or guarantee future performance.

During interim periods, we follow the accounting policies described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2016. Please refer to this when reviewing this Quarterly Report on Form 10-Q.

Management estimates and judgments are an integral part of financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). We believe that the critical accounting policies listed below address the more significant estimates required of Management when preparing our consolidated financial statements in accordance with GAAP. We consider an accounting estimate critical if changes in the estimate may have a material impact on our financial condition or results of operations. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, actual results could differ from the original estimates, requiring adjustment to these balances in future periods. The accounting policies that reflect our more significant estimates, judgments and assumptions and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are:

•Revenue recognition

•Net realizable value of inventory

•Valuation of goodwill

•Business combinations

•Income taxes

•Share-based compensation

During the fiscal first half of 2017, there were no significant changes in our estimates and critical accounting policies except for the accounting pronouncements that were recently adopted which are discussed below. Please refer to Note 1. Summary of Significant Accounting Policies of our Annual Report on Form 10-K for the fiscal year ended October 31, 2016, for a more complete discussion of our estimates and critical accounting policies.

During the fiscal first quarter of 2017, the Company identified and recorded an amount of $4.1 million, net of income tax expense, to reflect a net cumulative decrease to retained earnings as of the opening balance sheet for the fiscal year ended October 31, 2016 and a corresponding net increase in other current liabilities and deferred tax asset, all associated with an understatement of accruals for rebates in prior years. Accordingly, the Company has not revised income statements or cash flows of any periods as the impact to all periods is minimal since the understated rebates liability was accumulated primarily prior to fiscal 2014. Based upon evaluation and consideration of provisions under ASC 250, Accounting Changes and Error Corrections, that incorporates SEC Staff Accounting Bulletin (SAB) No.99, Materiality, we determined that the impact is not material to our prior year's consolidated financial statements. However, we have revised our prior year Balance Sheet as of October 31, 2016 in this Quarterly Report on Form 10-Q to reflect this adjustment.

Accounting Pronouncements Issued Not Yet Adopted

In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The ASU requires an entity to disaggregate the service cost component from the other components of net benefit cost. The service cost component is presented in the same line items as other compensation costs arising from services rendered by the pertinent employees during the period and the other components of net benefit costs are presented separately as other income/expense below income from operations. ASU 2017-07 will be effective for the Company in our fiscal year and interim periods beginning November 1, 2018.

In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and other (Topic 350): Simplifying the Test for Goodwill Impairment. FASB eliminated Step 2 from the goodwill impairment test, which required a hypothetical purchase price allocation. Under the amendments in this update, an entity should perform goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the carrying amount which exceeds the reporting unit’s fair value. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 will be effective for the Company's interim or annual goodwill impairment test in fiscal 2020 and is not expected to have a significant impact on the Company’s financial statements. Early adoption is permitted.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 provides guidance on the classification and presentation of changes in restricted cash and cash equivalents in the statement of cash flows. ASU 2016-18 will be effective for the Company in fiscal 2019 and is not expected to have a significant impact on the Company's Consolidated Statements of Cash Flows. Early adoption is permitted.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-01 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of ASU 2016-02, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2019.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 sets forth a new revenue recognition model that requires identifying the contract, identifying the performance obligations, determining the transaction price, allocating the transaction price to performance obligations and recognizing the revenue upon satisfaction of performance obligations. The amendments in the ASU can be applied either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the update recognized at the date of the initial application along with additional disclosures. We are currently evaluating the impact of ASU 2014-09, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2018.

Accounting Pronouncements Recently Adopted

In January 2017, the FASB issued ASU 2017-01, Business Combination (Topic 805): Clarifying the Definition of a Business. ASU 2017-01 provides a new framework for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The Company has elected to early adopt ASU 2017-01 effective in the fiscal second quarter, the adoption has no material impact for the Company.

In March 2016, the FASB issued ASU 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, to improve the accounting for share-based payments to employees. ASU 2016-09 requires excess tax benefits (windfall tax benefits) and tax deficiencies (shortfalls) to be recognized as income tax expense or benefit in the income statement when awards vest or are settled. Companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The standard also allows for additional employee tax withholding on the exercise or release of awards, without triggering liability classification of the award. Finally, the update allows an accounting policy election for the treatment of forfeitures of stock based awards. Companies can elect to continue to estimate forfeitures expected to occur, or account for forfeitures as they occur. The Company has elected to early adopt ASU 2016-09 effective November 1, 2016.

Accordingly, the Company recognized $17.9 million in deferred tax assets associated with excess tax benefits not previously recognized in deferred taxes as a cumulative-effect adjustment to retained earnings as of November 1, 2016. Furthermore, in accordance with the update, the Company recognized excess tax benefits as a discrete income tax benefit of $7.3 million during the fiscal first half of 2017 and accordingly, this is classified as an operating activity in the Consolidated Statements of Cash Flows on a prospective basis. The Company elected to continue to estimate forfeitures that are expected to occur when estimating the amount of compensation expense to record in each accounting period.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which requires entities to present all deferred tax assets and liabilities as noncurrent in the Balance Sheet. ASU 2015-17 can be early adopted for any period that has not been issued on a prospective or retrospective basis. The Company elected to early adopt this guidance on a prospective basis for the quarter ended January 31, 2017. No prior periods were retrospectively adjusted.

Acquisitions	6 Months Ended
Acquisitions	Apr. 30, 2017
Business Combinations [Abstract]
Acquisitions	Acquisitions Fiscal Year 2017 On November 4, 2016, we completed the acquisition of Wallace, the in-vitro fertilization (IVF) segment of Smiths Medical International, Ltd., a division of Smiths Group plc. The fair value of the consideration transferred for the acquisition was approximately $167.4 million in cash. Our preliminary allocation of the fair value of the purchase price includes $72.2 million in identifiable intangible assets, consisting of $66.5 million for technology, $3.2 million for trade name and $2.5 million for customer relationships; $94.8 million in goodwill; and $0.4 million in identifiable net assets. We are in the process of finalizing information related to assets and the corresponding effect on goodwill. Fiscal Year 2016 On March 31, 2016 we completed the acquisition of Genesis Genetics Inc., a U.S. based genetics laboratory specializing in preimplantation genetic screening and preimplantation genetic diagnosis used during the IVF process. The fair value of the consideration transferred for the acquisition was approximately $61.1 million in cash, $60.5 million net of cash acquired. Our allocation of the fair value of the purchase price includes $28.6 million in identifiable intangible assets, consisting of $25.2 million for customer relationships and $3.4 million for trade names; $28.7 million in goodwill; and $3.8 million in identifiable net tangible assets. On February 8, 2016, we completed the acquisition of The Pipette Company, an Australian manufacturer and distributor of micro pipettes for the Assisted Reproductive Technology market. The fair value of the consideration transferred for the acquisition was approximately $20.2 million in cash, $19.6 million net of cash acquired. Our allocation of the fair value of the purchase price includes $5.6 million in identifiable intangible assets, consisting of $5.2 million for customer relationships and $0.4 million for trade names; $15.0 million in goodwill; and $0.4 million in identifiable net liabilities. On December 17, 2015, we completed the acquisition of Research Instruments Limited, a UK manufacturer and supplier of IVF medical devices and systems. The fair value of the consideration transferred for the acquisition was approximately $53.6 million in cash, $50.0 million net of cash acquired. Our allocation of the fair value of the purchase price includes $10.3 million in identifiable intangible assets, consisting of $6.2 million for developed technology, $2.2 million of trade names and $1.9 million for customer relationships; $35.8 million in goodwill; and $7.6 million in identifiable net tangible assets. We believe these acquisitions strengthen CooperSurgical's business through the addition of new or complementary products and services within IVF and our genetic testing platform. The pro forma results of operations of these acquisitions have not been presented because the effects of the business combinations described above, individually and in the aggregate, were not material to our consolidated results of operations.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Restructuring and Integration Costs

6 Months Ended

Apr. 30, 2017

Restructuring and Related Activities [Abstract]

Restructuring and Integration Costs

2014 Sauflon Integration Plan

During the fiscal fourth quarter of 2014 and in connection with the Sauflon acquisition, our CooperVision business unit initiated restructuring and integration activities to optimize operational synergies of the combined companies. These activities include product and equipment rationalization, workforce reductions and consolidation of duplicative facilities. At October 31, 2016, our activities related to this restructuring and integration plan were essentially complete. The total restructuring costs under this plan were $148.3 million. There were no charges related to the 2014 Sauflon Integration Plan in fiscal first half of 2017.

In the three and six month periods ended April 30, 2016, we recorded in cost of sales $4.2 million and $14.7 million of expense, respectively, arising from production-related asset disposals and accelerated depreciation on equipment, primarily related to our hydrogel lenses, based on our review of products, materials and manufacturing processes of Sauflon. We recorded in cost of sales, employee termination costs of $0.7 million and $0.5 million in the three and six month periods ended April 30, 2016, respectively. We recorded $0.1 million of employee termination costs and $0.3 million for lease termination costs in selling, general and administrative expense in the six months ended April 30, 2016. We also recorded in research and development expense $0.1 million of employee termination costs in the six months ended April 30, 2016. In addition, CooperVision incurred $2.1 million and $10.0 million of integration costs included in operating expenses in the three and six month periods ended April 30, 2016, respectively.

A summary of the cumulative total restructuring costs by major component recognized as of October 31, 2016, is as follows:



(In millions)	Employee-related		Facilities-related		Product Rationalization		Total
Cumulative amounts incurred as of October 31, 2016	$	17.8	$	1.1	$	129.4	$	148.3

The following table summarizes the restructuring activities by major component for the fiscal year ended October 31, 2016 and the six months ended April 30, 2017:



(In millions)	Employee-related			Facilities-related			Product Rationalization			Total

Balance at October 31, 2015	$	8.6		$	0.3		$	—		$	8.9
Additions during fiscal 2016	—			0.2			56.4			56.6
Payments during the fiscal year	(5.2		)	(0.2		)	—			(5.4		)
Non-cash adjustments (a) (b)	(0.6		)	—			(56.4		)	(57.0		)
Balance at October 31, 2016	$	2.8		$	0.3		$	—		$	3.1
Payments during the six months ended April 30, 2017	(1.5		)	—			—			(1.5		)
Non-cash adjustments (a)	(0.7		)	(0.3		)	—			(1.0		)
Balance at April 30, 2017	$	0.6		$	—		$	—		$	0.6

(a) Represent adjustments for currency translation and accrual releases for employee and facilities-related.

(b) Represents equipment disposals, inventory write-offs and accelerated depreciation for product rationalization.

Inventories

6 Months Ended

Apr. 30, 2017

Inventory Disclosure [Abstract]

Inventories



(In millions)	April 30, 2017		October 31, 2016
Raw materials	$	101.1	$	86.0
Work-in-process	14.7		12.6
Finished goods	321.8		319.1
	$	437.6	$	417.7

Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

Intangible Assets

6 Months Ended

Apr. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Goodwill



(In millions)	CooperVision			CooperSurgical			Total
Balance at October 31, 2015	$	1,827.6		$	369.5		$	2,197.1
Net additions during the year ended October 31, 2016	9.1			156.9			166.0
Translation	(190.3		)	(8.1		)	(198.4		)
Balance at October 31, 2016	1,646.4			518.3			2,164.7
Net (reductions) additions during the six months ended April 30, 2017	(1.1		)	94.8			93.7
Translation	43.4			0.9			44.3
Balance at April 30, 2017	$	1,688.7		$	614.0		$	2,302.7

We performed our annual impairment assessment in our fiscal third quarter of 2016, and our analysis indicated that we had no impairment of goodwill. As described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2016, we will continue to monitor conditions and changes which could indicate that our recorded goodwill may be impaired.

Other Intangible Assets



	As of April 30, 2017				As of October 31, 2016
(In millions)	Gross Carrying Amount		Accumulated Amortization & Translation		Gross Carrying Amount		Accumulated Amortization & Translation
Trademarks	$	40.1	$	8.4	$	36.6	$	6.8
Technology	422.7		156.5		354.8		139.3
Customer relationships	291.1		132.8		285.7		121.9
License and distribution rights and other	68.2		39.4		65.8		33.8
	822.1		$	337.1	742.9		$	301.8
Less: accumulated amortization and translation	337.1				301.8
Other intangible assets, net	$	485.0			$	441.1

We estimate that amortization expense for our existing other intangible assets at April 30, 2017, will be $66.7 million in fiscal 2017, $64.5 million in fiscal 2018, $62.1 million in fiscal 2019, $52.2 million in fiscal 2020 and $50.7 million in fiscal 2021.

Debt

6 Months Ended

Apr. 30, 2017

Debt Disclosure [Abstract]

Debt



(In millions)	April 30, 2017			October 31, 2016
Short-term:
Overdraft and other credit facilities	$	31.3		$	17.1
Current portion of long-term debt	11.3			210.7
Less: unamortized debt issuance cost on term loans	(1.3		)	(1.5		)
	$	41.3		$	226.3
Long-term:
Credit agreement	$	245.0		$	—
Term loans	1,103.8			1,111.2
Other	0.2			0.2
Less: unamortized debt issuance cost on term loans	(3.4		)	(4.0		)
	$	1,345.6		$	1,107.4

Revolving Credit and Term Loan Agreement on March 1, 2016 (2016 Credit Agreement)

On March 1, 2016, we entered into a new Revolving Credit and Term Loan Agreement (2016 Credit Agreement), among the Company, CooperVision International Holding Company, LP, the lenders party thereto and KeyBank National Association, as administrative agent. The 2016 Credit Agreement provides for a multicurrency revolving credit facility in an aggregate principal amount of $1.0 billion and a term loan facility in an aggregate principal amount of $830.0 million, each of which, unless terminated earlier, mature on March 1, 2021. In addition, we have the ability from time to time to request an increase to the size of the revolving credit facility or establish one or more new term loans under the term loan facility in an aggregate amount up to $750.0 million, subject to the discretionary participation of the lenders.

Amounts outstanding under the 2016 Credit Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBO rate or adjusted foreign currency rate (each as defined in the 2016 Credit Agreement), plus, in each case, an applicable rate of between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBO rate or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2016 Credit Agreement.

We pay an annual commitment fee that ranges from 0.125% to 0.25% of the unused portion of the revolving credit facility depending on certain financial ratios. In addition to the annual commitment fee described above, we are also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the 2016 Credit Agreement.

The 2016 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require us to maintain a certain total leverage ratio and interest coverage ratio, each as defined in the 2016 Credit Agreement:


•	Interest Coverage Ratio, as defined, to be at least 3.00 to 1.00 at all times.


•	Total Leverage Ratio, as defined, to be no higher than 3.75 to 1.00.

At April 30, 2017, we were in compliance with the Interest Coverage Ratio at 23.95 to 1.00 and the Total Leverage Ratio at 1.87 to 1.00.

At April 30, 2017, we had $830.0 million outstanding under the term loan and $754.8 million available under the revolving credit agreement.

Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 for more details.

$700.0 million Term Loan and $300 million Term Loan

On August 4, 2014, we entered into a three-year, $700.0 million, senior unsecured term loan agreement by and among the Company, the lenders party thereto and KeyBank National Association as administrative agent (as subsequently amended, the 2014 Term Loan Agreement) with a maturity date of August 4, 2017. In August 2014, we utilized this facility to fund the acquisition of Sauflon, as well as to provide working capital and for general corporate purposes. We repaid $493.0 million of the outstanding balance in fiscal 2016 and fully repaid the remaining outstanding balance of $207.0 million in the fiscal second quarter of 2017 using the funds from the 2016 Credit Agreement, as well as from cash provided by operations.

At April 30, 2017, we had no outstanding balance under the 2014 Term Loan.

On September 12, 2013, the Company entered into a five-year, $300.0 million, senior unsecured term loan agreement by and among the Company; the lenders party thereto and KeyBank National Association, as administrative agent (as subsequently amended, the 2013 Term Loan Agreement), with a maturity date of September 12, 2018, subject to amortization of principal of 5% per annum payable quarterly beginning October 31, 2016, with the balance payable at maturity. In fiscal 2016, we repaid $15.0 million of the outstanding balance using the funds from the 2016 Credit Agreement.

At April 30, 2017, we had $285.0 million outstanding under the 2013 Term Loan. Subsequent to the end of fiscal second quarter, we fully repaid the remaining $285.0 million in May 2017 using the funds from the 2016 Credit Agreement.

Amounts outstanding under the 2014 and 2013 Term Loan Agreements (Term Loan Agreements) bear interest, at our option, at either the base rate, or the adjusted LIBO rate (each as defined in the Term Loan Agreements), plus, in each case, an applicable rate of between 0.00% and 0.50% in respect of base rate loans and between 0.75% and 1.50% in respect of adjusted LIBO rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the Term Loan Agreements.

These Term Loan Agreements contain customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the agreements, consistent with the 2016 Credit Agreement discussed above.

Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 for more details.

Income Taxes	6 Months Ended
Income Taxes	Apr. 30, 2017
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income Taxes	Income Taxes Our effective tax rate (ETR) (provision for income taxes divided by pretax income) for the fiscal first half of 2017 was 4.7%. Our year-to-date results reflect the projected fiscal year ETR, plus any discrete items. The ETR used to record the provision for income taxes for the fiscal first half of 2016 was 5.4%. The decrease in the effective tax rate in the fiscal first half of 2017 reflects a shift in our geographic mix of income as well as the benefit from adopting ASU 2016-09 (Excess tax benefit from share-based compensation). We recognize the benefit from a tax position only if it is more likely than not that the position would be sustained upon audit based solely on the technical merits of the tax position. At November 1, 2016, Cooper had unrecognized tax benefits of $39.9 million, of which, if recognized, $29.7 million would impact our ETR. For the fiscal first half of 2017, there were no material changes to the total amount of unrecognized tax benefits. We have accrued $3.7 million of interest and penalties as of November 1, 2016. It is our policy to recognize the items of interest and penalties directly related to income taxes as additional income tax expense. Included in the balance of unrecognized tax benefits at November 1, 2016, is $1.6 million related to tax positions for which it is reasonably possible that the total amounts could significantly change during the next twelve months. This amount represents a decrease in unrecognized tax benefits related to expiring statutes in various jurisdictions worldwide and relates primarily to transfer pricing matters. At April 30, 2017, the tax years for which Cooper remains subject to United States Federal income tax assessment upon examination are 2014 through 2016. Cooper remains subject to income tax examinations in other significant tax jurisdictions including the United Kingdom, Japan, France and Australia for the tax years 2013 through 2016.

Earnings Per Share

6 Months Ended

Apr. 30, 2017

Earnings Per Share [Abstract]

Earnings Per Share



Periods Ended April 30,	Three Months				Six Months
(In millions, except per share amounts)	2017		2016		2017		2016
Net income attributable to Cooper stockholders	$	104.9	$	74.1	$	180.7	$	125.5
Basic:
Weighted average common shares	49.0		48.4		48.9		48.4
Basic earnings per common share attributable to Cooper stockholders	$	2.14	$	1.53	$	3.70	$	2.59
Diluted:
Weighted average common shares	49.0		48.4		48.9		48.4
Effect of potential dilutive common shares	0.5		0.5		0.6		0.4
Diluted weighted average common shares	49.5		48.9		49.5		48.8
Diluted earnings per common share attributable to Cooper stockholders	$	2.12	$	1.52	$	3.65	$	2.57

The following table sets forth stock options to purchase Cooper’s common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:



Periods Ended April 30,	Three Months			Six Months
(In thousands, except exercise prices)	2017		2016	2017	2016
Numbers of stock option shares excluded	192		537	234	537
Range of exercise prices	$	175.31	$131.60-$162.69	$162.28-$175.31	$131.60-$162.69
Numbers of restricted stock units excluded	1		7	1	2

Share-Based Compensation Plans

6 Months Ended

Apr. 30, 2017

Share-based Compensation [Abstract]

Share-Based Compensation Plans

Cooper has several share-based compensation plans that are described in the Company’s Annual Report on Form 10‑K for the fiscal year ended October 31, 2016. The compensation expense and related income tax benefit recognized in our consolidated condensed financial statements for share-based awards were as follows:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2017		2016		2017		2016
Selling, general and administrative expense	$	7.6	$	7.0	$	17.2	$	12.8
Cost of sales	0.8		0.7		2.0		1.2
Research and development expense	0.3		0.2		0.6		0.6
Total share-based compensation expense	$	8.7	$	7.9	$	19.8	$	14.6
Related income tax benefit	$	2.6	$	2.3	$	5.9	$	4.3

We capitalized share-based compensation expense as part of the cost of inventory in the amounts of $0.8 million and $2.0 million during the three and six months ended April 30, 2017, respectively; and $0.7 million and $1.2 million during the three and six months ended April 30, 2016, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Stockholders' Equity

6 Months Ended

Apr. 30, 2017

Equity [Abstract]

Stockholders' Equity

Stockholders’ Equity

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):



(In millions)	Foreign Currency Translation Adjustment			Minimum Pension Liability			Total
Balance at October 31, 2015	$	(171.8	)	$	(19.8	)	$	(191.6	)
Gross change in value during the year ended October 31, 2016	(289.6		)	(13.7		)	(303.3		)
Tax effect for the period	—			5.3			5.3
Balance at October 31, 2016	$	(461.4	)	$	(28.2	)	$	(489.6	)
Gross change in value during the six months ended April 30, 2017	66.5			—			66.5
Balance at April 30, 2017	$	(394.9	)	$	(28.2	)	$	(423.1	)

Share Repurchases

In December 2011, our Board of Directors authorized the 2012 Share Repurchase Program and through subsequent amendments, the most recent in March 2017, the total repurchase authorization was increased from $500.0 million to $1.0 billion of the Company’s common stock in March 2017. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements. In the fiscal second quarter of 2017, we repurchased 150 thousand shares of the Company's common stock for $29.5 million, at an average purchase price of $196.82 per share. We did not repurchase shares during the fiscal first half of 2016. At April 30, 2017, approximately $589.0 million remains authorized for repurchase under the program.

Dividends

We paid a semiannual dividend of approximately $1.5 million or 3 cents per share on February 9, 2017, to stockholders of record on January 23, 2017.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Apr. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements At April 30, 2017 and October 31, 2016, the carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms. Assets and liabilities are measured and reported at fair value per related accounting standards that define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. We believe that the balances of our revolving credit agreement and term loans approximated their fair values at April 30, 2017 and October 31, 2016 and are categorized as Level 2 of the fair value hierarchy. At April 30, 2017 and October 31, 2016, we do not have derivative assets and liabilities balance. We may from time-to-time use interest rate swaps to maintain our desired mix of fixed-rate and variable-rate debt.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Employee Benefits

6 Months Ended

Apr. 30, 2017

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Employee Benefits

Cooper’s Retirement Income Plan (Plan), a defined benefit plan, covers substantially all full-time United States employees. Our contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. Cooper pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds.

Our results of operations for the three and six months ended April 30, 2017 and 2016 reflect the following components of net periodic pension costs:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2017			2016			2017			2016
Service cost	$	2.5		$	2.3		$	5.0		$	4.6
Interest cost	1.1			1.2			2.2			2.5
Expected return on plan assets	(1.8		)	(1.6		)	(3.6		)	(3.3		)
Recognized net actuarial loss	0.7			0.4			1.4			0.8
Net periodic pension cost	$	2.5		$	2.3		$	5.0		$	4.6

We contributed $2.5 million to the Plan in the first half of fiscal 2017, and expect to contribute an additional $7.5 million during the remainder of fiscal 2017. We contributed $2.5 million to the Plan in the first half of fiscal 2016. The expected rate of return on plan assets for determining net periodic pension cost is 8%.

Contingencies	6 Months Ended
Contingencies	Apr. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Since March 2015, over 50 putative class action complaints were filed by contact lens consumers alleging that contact lens manufacturers, in conjunction with their respective Unilateral Pricing Policy (UPP), conspired to reach agreements between each other and certain distributors and retailers regarding the prices at which certain contact lenses could be sold to consumers. The plaintiffs are seeking damages against CooperVision, Inc., other contact lens manufacturers, distributors and retailers, in various courts around the United States. In June 2015, all of the class action cases were consolidated and transferred to the United States District Court for the Middle District of Florida. CooperVision and the other defendants jointly filed a motion to dismiss the complaints in December 2015. In June 2016, the motion to dismiss with respect to claims brought under the Maryland Consumer Protection Act was granted, but the motion to dismiss with respect to claims brought under Section 1 of the Sherman Act and other state laws was denied. The actions currently are in discovery. In March 2017, the plaintiffs filed a motion for class certification. CooperVision denies the allegations and intends to defend the actions vigorously. At this time, we do not believe a loss or adverse effect on our financial condition is probable nor is any range of potential loss reasonably estimable. The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that an estimate of possible loss or a range of loss can be made at this time.

- Definition

The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

+ Details

Business Segment Information

6 Months Ended

Apr. 30, 2017

Segment Reporting [Abstract]

Business Segment Information

Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results.

Identifiable assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets.

Segment information:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2017			2016			2017			2016
CooperVision net sales by category:
Toric lens	$	131.8		$	120.5		$	252.5		$	228.0
Multifocal lens	42.9			42.5			85.3			82.9
Single-use sphere lens	104.1			97.6			203.7			188.4
Non single-use sphere and other	129.7			130.6			256.3			256.3
Total CooperVision net sales	408.5			391.2			797.8			755.6
CooperSurgical net sales	113.9			92.6			223.7			177.8
Total net sales	$	522.4		$	483.8		$	1,021.5		$	933.4
Operating income (loss):
CooperVision	$	112.1		$	83.6		$	199.4		$	136.4
CooperSurgical	16.8			17.7			33.3			33.1
Corporate	(11.8		)	(11.5		)	(24.9		)	(22.3		)
Total operating income	117.1			89.8			207.8			147.2
Interest expense	7.7			7.6			15.0			12.9
Other (income) expense, net	(0.1		)	(0.4		)	3.2			0.9
Income before income taxes	$	109.5		$	82.6		$	189.6		$	133.4



(In millions)	April 30, 2017		October 31, 2016
Identifiable assets:
CooperVision	$	3,454.0	$	3,382.4
CooperSurgical	1,086.4		907.1
Corporate	209.4		189.1
Total	$	4,749.8	$	4,478.6

Geographic information:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2017		2016		2017		2016
Net sales to external customers by country of domicile:
United States	$	235.3	$	221.4	$	459.5	$	428.2
Europe	175.6		165.9		343.9		323.0
Rest of world	111.5		96.5		218.1		182.2
Total	$	522.4	$	483.8	$	1,021.5	$	933.4



(In millions)	April 30, 2017		October 31, 2016
Net property, plant and equipment by country of domicile:
United States	$	463.4	$	464.1
Europe	342.2		334.4
Rest of world	80.9		79.2
Total	$	886.5	$	877.7

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

General (Policies)	6 Months Ended
General (Policies)	Apr. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounting Changes and Error Corrections	During the fiscal first quarter of 2017, the Company identified and recorded an amount of $4.1 million, net of income tax expense, to reflect a net cumulative decrease to retained earnings as of the opening balance sheet for the fiscal year ended October 31, 2016 and a corresponding net increase in other current liabilities and deferred tax asset, all associated with an understatement of accruals for rebates in prior years. Accordingly, the Company has not revised income statements or cash flows of any periods as the impact to all periods is minimal since the understated rebates liability was accumulated primarily prior to fiscal 2014. Based upon evaluation and consideration of provisions under ASC 250, Accounting Changes and Error Corrections, that incorporates SEC Staff Accounting Bulletin (SAB) No.99, Materiality, we determined that the impact is not material to our prior year's consolidated financial statements. However, we have revised our prior year Balance Sheet as of October 31, 2016 in this Quarterly Report on Form 10-Q to reflect this adjustment.
Accounting Pronouncements Issued Not Yet Adopted and Accounting Pronouncements Recently Adopted	Accounting Pronouncements Issued Not Yet Adopted In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The ASU requires an entity to disaggregate the service cost component from the other components of net benefit cost. The service cost component is presented in the same line items as other compensation costs arising from services rendered by the pertinent employees during the period and the other components of net benefit costs are presented separately as other income/expense below income from operations. ASU 2017-07 will be effective for the Company in our fiscal year and interim periods beginning November 1, 2018. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and other (Topic 350): Simplifying the Test for Goodwill Impairment. FASB eliminated Step 2 from the goodwill impairment test, which required a hypothetical purchase price allocation. Under the amendments in this update, an entity should perform goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the carrying amount which exceeds the reporting unit’s fair value. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 will be effective for the Company's interim or annual goodwill impairment test in fiscal 2020 and is not expected to have a significant impact on the Company’s financial statements. Early adoption is permitted. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 provides guidance on the classification and presentation of changes in restricted cash and cash equivalents in the statement of cash flows. ASU 2016-18 will be effective for the Company in fiscal 2019 and is not expected to have a significant impact on the Company's Consolidated Statements of Cash Flows. Early adoption is permitted. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-01 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of ASU 2016-02, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2019. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 sets forth a new revenue recognition model that requires identifying the contract, identifying the performance obligations, determining the transaction price, allocating the transaction price to performance obligations and recognizing the revenue upon satisfaction of performance obligations. The amendments in the ASU can be applied either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the update recognized at the date of the initial application along with additional disclosures. We are currently evaluating the impact of ASU 2014-09, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2018. Accounting Pronouncements Recently Adopted In January 2017, the FASB issued ASU 2017-01, Business Combination (Topic 805): Clarifying the Definition of a Business. ASU 2017-01 provides a new framework for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The Company has elected to early adopt ASU 2017-01 effective in the fiscal second quarter, the adoption has no material impact for the Company. In March 2016, the FASB issued ASU 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, to improve the accounting for share-based payments to employees. ASU 2016-09 requires excess tax benefits (windfall tax benefits) and tax deficiencies (shortfalls) to be recognized as income tax expense or benefit in the income statement when awards vest or are settled. Companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The standard also allows for additional employee tax withholding on the exercise or release of awards, without triggering liability classification of the award. Finally, the update allows an accounting policy election for the treatment of forfeitures of stock based awards. Companies can elect to continue to estimate forfeitures expected to occur, or account for forfeitures as they occur. The Company has elected to early adopt ASU 2016-09 effective November 1, 2016. Accordingly, the Company recognized $17.9 million in deferred tax assets associated with excess tax benefits not previously recognized in deferred taxes as a cumulative-effect adjustment to retained earnings as of November 1, 2016. Furthermore, in accordance with the update, the Company recognized excess tax benefits as a discrete income tax benefit of $7.3 million during the fiscal first half of 2017 and accordingly, this is classified as an operating activity in the Consolidated Statements of Cash Flows on a prospective basis. The Company elected to continue to estimate forfeitures that are expected to occur when estimating the amount of compensation expense to record in each accounting period. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which requires entities to present all deferred tax assets and liabilities as noncurrent in the Balance Sheet. ASU 2015-17 can be early adopted for any period that has not been issued on a prospective or retrospective basis. The Company elected to early adopt this guidance on a prospective basis for the quarter ended January 31, 2017. No prior periods were retrospectively adjusted.

Restructuring and Integration Costs (Tables)

6 Months Ended

Apr. 30, 2017

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Costs

A summary of the cumulative total restructuring costs by major component recognized as of October 31, 2016, is as follows:



(In millions)	Employee-related		Facilities-related		Product Rationalization		Total
Cumulative amounts incurred as of October 31, 2016	$	17.8	$	1.1	$	129.4	$	148.3

The following table summarizes the restructuring activities by major component for the fiscal year ended October 31, 2016 and the six months ended April 30, 2017:



(In millions)	Employee-related			Facilities-related			Product Rationalization			Total

Balance at October 31, 2015	$	8.6		$	0.3		$	—		$	8.9
Additions during fiscal 2016	—			0.2			56.4			56.6
Payments during the fiscal year	(5.2		)	(0.2		)	—			(5.4		)
Non-cash adjustments (a) (b)	(0.6		)	—			(56.4		)	(57.0		)
Balance at October 31, 2016	$	2.8		$	0.3		$	—		$	3.1
Payments during the six months ended April 30, 2017	(1.5		)	—			—			(1.5		)
Non-cash adjustments (a)	(0.7		)	(0.3		)	—			(1.0		)
Balance at April 30, 2017	$	0.6		$	—		$	—		$	0.6

(a) Represent adjustments for currency translation and accrual releases for employee and facilities-related.

(b) Represents equipment disposals, inventory write-offs and accelerated depreciation for product rationalization.

Inventories (Tables)

6 Months Ended

Apr. 30, 2017

Inventory Disclosure [Abstract]

Schedule of Inventories



(In millions)	April 30, 2017		October 31, 2016
Raw materials	$	101.1	$	86.0
Work-in-process	14.7		12.6
Finished goods	321.8		319.1
	$	437.6	$	417.7

Intangible Assets (Tables)

6 Months Ended

Apr. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Goodwill



(In millions)	CooperVision			CooperSurgical			Total
Balance at October 31, 2015	$	1,827.6		$	369.5		$	2,197.1
Net additions during the year ended October 31, 2016	9.1			156.9			166.0
Translation	(190.3		)	(8.1		)	(198.4		)
Balance at October 31, 2016	1,646.4			518.3			2,164.7
Net (reductions) additions during the six months ended April 30, 2017	(1.1		)	94.8			93.7
Translation	43.4			0.9			44.3
Balance at April 30, 2017	$	1,688.7		$	614.0		$	2,302.7

Schedule of Other Intangible Assets

Other Intangible Assets



	As of April 30, 2017				As of October 31, 2016
(In millions)	Gross Carrying Amount		Accumulated Amortization & Translation		Gross Carrying Amount		Accumulated Amortization & Translation
Trademarks	$	40.1	$	8.4	$	36.6	$	6.8
Technology	422.7		156.5		354.8		139.3
Customer relationships	291.1		132.8		285.7		121.9
License and distribution rights and other	68.2		39.4		65.8		33.8
	822.1		$	337.1	742.9		$	301.8
Less: accumulated amortization and translation	337.1				301.8
Other intangible assets, net	$	485.0			$	441.1

Debt (Tables)

6 Months Ended

Apr. 30, 2017

Debt Disclosure [Abstract]

Schedule of Debt



(In millions)	April 30, 2017			October 31, 2016
Short-term:
Overdraft and other credit facilities	$	31.3		$	17.1
Current portion of long-term debt	11.3			210.7
Less: unamortized debt issuance cost on term loans	(1.3		)	(1.5		)
	$	41.3		$	226.3
Long-term:
Credit agreement	$	245.0		$	—
Term loans	1,103.8			1,111.2
Other	0.2			0.2
Less: unamortized debt issuance cost on term loans	(3.4		)	(4.0		)
	$	1,345.6		$	1,107.4

Earnings Per Share (Tables)

6 Months Ended

Apr. 30, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share



Periods Ended April 30,	Three Months				Six Months
(In millions, except per share amounts)	2017		2016		2017		2016
Net income attributable to Cooper stockholders	$	104.9	$	74.1	$	180.7	$	125.5
Basic:
Weighted average common shares	49.0		48.4		48.9		48.4
Basic earnings per common share attributable to Cooper stockholders	$	2.14	$	1.53	$	3.70	$	2.59
Diluted:
Weighted average common shares	49.0		48.4		48.9		48.4
Effect of potential dilutive common shares	0.5		0.5		0.6		0.4
Diluted weighted average common shares	49.5		48.9		49.5		48.8
Diluted earnings per common share attributable to Cooper stockholders	$	2.12	$	1.52	$	3.65	$	2.57

Schedule of Stock Options to Purchase Common Stock Not Included in Diluted Net Income Per Share Calculation



Periods Ended April 30,	Three Months			Six Months
(In thousands, except exercise prices)	2017		2016	2017	2016
Numbers of stock option shares excluded	192		537	234	537
Range of exercise prices	$	175.31	$131.60-$162.69	$162.28-$175.31	$131.60-$162.69
Numbers of restricted stock units excluded	1		7	1	2

Share-Based Compensation Plans (Tables)

6 Months Ended

Apr. 30, 2017

Share-based Compensation [Abstract]

Schedule of Compensation Expense and Related Income Tax Benefit for Share-Based Awards

The compensation expense and related income tax benefit recognized in our consolidated condensed financial statements for share-based awards were as follows:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2017		2016		2017		2016
Selling, general and administrative expense	$	7.6	$	7.0	$	17.2	$	12.8
Cost of sales	0.8		0.7		2.0		1.2
Research and development expense	0.3		0.2		0.6		0.6
Total share-based compensation expense	$	8.7	$	7.9	$	19.8	$	14.6
Related income tax benefit	$	2.6	$	2.3	$	5.9	$	4.3

Stockholders' Equity Stockholders' Equity (Tables)

6 Months Ended

Apr. 30, 2017

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):



(In millions)	Foreign Currency Translation Adjustment			Minimum Pension Liability			Total
Balance at October 31, 2015	$	(171.8	)	$	(19.8	)	$	(191.6	)
Gross change in value during the year ended October 31, 2016	(289.6		)	(13.7		)	(303.3		)
Tax effect for the period	—			5.3			5.3
Balance at October 31, 2016	$	(461.4	)	$	(28.2	)	$	(489.6	)
Gross change in value during the six months ended April 30, 2017	66.5			—			66.5
Balance at April 30, 2017	$	(394.9	)	$	(28.2	)	$	(423.1	)

Employee Benefits (Tables)

6 Months Ended

Apr. 30, 2017

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Schedule of Components of Net Periodic Pension Costs

Our results of operations for the three and six months ended April 30, 2017 and 2016 reflect the following components of net periodic pension costs:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2017			2016			2017			2016
Service cost	$	2.5		$	2.3		$	5.0		$	4.6
Interest cost	1.1			1.2			2.2			2.5
Expected return on plan assets	(1.8		)	(1.6		)	(3.6		)	(3.3		)
Recognized net actuarial loss	0.7			0.4			1.4			0.8
Net periodic pension cost	$	2.5		$	2.3		$	5.0		$	4.6

Business Segment Information (Tables)

6 Months Ended

Apr. 30, 2017

Segment Reporting [Abstract]

Schedule of Segment Information

Segment information:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2017			2016			2017			2016
CooperVision net sales by category:
Toric lens	$	131.8		$	120.5		$	252.5		$	228.0
Multifocal lens	42.9			42.5			85.3			82.9
Single-use sphere lens	104.1			97.6			203.7			188.4
Non single-use sphere and other	129.7			130.6			256.3			256.3
Total CooperVision net sales	408.5			391.2			797.8			755.6
CooperSurgical net sales	113.9			92.6			223.7			177.8
Total net sales	$	522.4		$	483.8		$	1,021.5		$	933.4
Operating income (loss):
CooperVision	$	112.1		$	83.6		$	199.4		$	136.4
CooperSurgical	16.8			17.7			33.3			33.1
Corporate	(11.8		)	(11.5		)	(24.9		)	(22.3		)
Total operating income	117.1			89.8			207.8			147.2
Interest expense	7.7			7.6			15.0			12.9
Other (income) expense, net	(0.1		)	(0.4		)	3.2			0.9
Income before income taxes	$	109.5		$	82.6		$	189.6		$	133.4

Schedule of Identifiable Assets by Segment



(In millions)	April 30, 2017		October 31, 2016
Identifiable assets:
CooperVision	$	3,454.0	$	3,382.4
CooperSurgical	1,086.4		907.1
Corporate	209.4		189.1
Total	$	4,749.8	$	4,478.6

Schedule of Net Sales to External Customers by Country of Domicile

Geographic information:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2017		2016		2017		2016
Net sales to external customers by country of domicile:
United States	$	235.3	$	221.4	$	459.5	$	428.2
Europe	175.6		165.9		343.9		323.0
Rest of world	111.5		96.5		218.1		182.2
Total	$	522.4	$	483.8	$	1,021.5	$	933.4

Schedule of Long-Lived Assets by Country of Domicile



(In millions)	April 30, 2017		October 31, 2016
Net property, plant and equipment by country of domicile:
United States	$	463.4	$	464.1
Europe	342.2		334.4
Rest of world	80.9		79.2
Total	$	886.5	$	877.7

General Accounting Pronouncements (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jan. 31, 2017	Apr. 30, 2017	Nov. 01, 2016
Accounting Standards Update 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Excess tax benefit, amount		$ 7.3
Retained Earnings [Member] \| Accounting Standards Update 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment			$ 17.9
Rebate Accruals [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative Effect on Retained Earnings, Net of Tax	$ (4.1)
Cumulative effect on retained earnings, net of tax	$ 4.1

- Definition

Amount of cumulative effect of the change in accounting principle or new accounting pronouncement on retained earnings or other components of equity or net assets in the statement of financial position as of the beginning of the earliest period presented.

+ References + Details

Acquisitions (Details) - USD ($) $ in Millions	Nov. 04, 2016	Mar. 31, 2016	Feb. 08, 2016	Dec. 17, 2015
Wallace [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition	Nov. 04, 2016
Total purchase consideration	$ 167.4
Identifiable intangible assets	72.2
Goodwill, acquired during period	94.8
Recognized identifiable assets (liabilities)	0.4
Genesis Genetics [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition		Mar. 31, 2016
Total purchase consideration		$ 61.1
Identifiable intangible assets		28.6
Goodwill, acquired during period		28.7
Recognized identifiable assets (liabilities)		3.8
Payments to acquire businesses, net of cash acquired		60.5
The Pipette Company [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition			Feb. 08, 2016
Total purchase consideration			$ 20.2
Identifiable intangible assets			5.6
Goodwill, acquired during period			15.0
Recognized identifiable assets (liabilities)			(0.4)
Payments to acquire businesses, net of cash acquired			19.6
Research Instruments [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition				Dec. 17, 2015
Total purchase consideration				$ 53.6
Identifiable intangible assets				10.3
Goodwill, acquired during period				35.8
Recognized identifiable assets (liabilities)				7.6
Payments to acquire businesses, net of cash acquired				50.0
Technology \| Wallace [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	66.5
Technology \| Research Instruments [Member]
Business Acquisition [Line Items]
Identifiable intangible assets				6.2
Trade Names [Member] \| Wallace [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	3.2
Trade Names [Member] \| Genesis Genetics [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		3.4
Trade Names [Member] \| The Pipette Company [Member]
Business Acquisition [Line Items]
Identifiable intangible assets			0.4
Trade Names [Member] \| Research Instruments [Member]
Business Acquisition [Line Items]
Identifiable intangible assets				2.2
Customer relationships \| Wallace [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 2.5
Customer relationships \| Genesis Genetics [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 25.2
Customer relationships \| The Pipette Company [Member]
Business Acquisition [Line Items]
Identifiable intangible assets			$ 5.2
Customer relationships \| Research Instruments [Member]
Business Acquisition [Line Items]
Identifiable intangible assets				$ 1.9

Restructuring and Integration Costs (Narrative) (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Apr. 30, 2016	Apr. 30, 2016	Oct. 31, 2016	Apr. 30, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Activities, Completion Date			Oct. 31, 2016
Sauflon [Member]
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016			$ 148,300,000	$ 0
Additions during the period			56,600,000
Integration costs	$ 2,100,000	$ 10,000,000
Sauflon [Member] \| Product Rationalization
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016			129,400,000
Additions during the period			56,400,000
Sauflon [Member] \| Product Rationalization \| Cost of sales [Member]
Restructuring Cost and Reserve [Line Items]
Additions during the period	4,200,000	14,700,000
Sauflon [Member] \| Employee-related
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016			17,800,000
Additions during the period			0
Sauflon [Member] \| Employee-related \| Cost of sales [Member]
Restructuring Cost and Reserve [Line Items]
Additions during the period	$ 700,000	500,000
Sauflon [Member] \| Employee-related \| Selling, general and administrative expense [Member]
Restructuring Cost and Reserve [Line Items]
Additions during the period		100,000
Sauflon [Member] \| Employee-related \| Research and development expense [Member]
Restructuring Cost and Reserve [Line Items]
Additions during the period		100,000
Sauflon [Member] \| Facilities-related
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016			1,100,000
Additions during the period			$ 200,000
Sauflon [Member] \| Facilities-related \| Selling, general and administrative expense [Member]
Restructuring Cost and Reserve [Line Items]
Additions during the period		$ 300,000

Restructuring and Integration Costs (Details) - Sauflon [Member] - USD ($)	6 Months Ended	12 Months Ended
	Apr. 30, 2017	Oct. 31, 2016
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016	$ 0	$ 148,300,000
Restructuring Reserve [Roll Forward]
Balance, beginning	3,100,000	8,900,000
Additions (reductions) during the period		56,600,000
Payments during the period	(1,500,000)	(5,400,000)
Non-cash adjustments	(1,000,000)	(57,000,000)
Balance, ending	600,000	3,100,000
Employee-related
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016		17,800,000
Restructuring Reserve [Roll Forward]
Balance, beginning	2,800,000	8,600,000
Additions (reductions) during the period		0
Payments during the period	(1,500,000)	(5,200,000)
Non-cash adjustments	(700,000)	(600,000)
Balance, ending	600,000	2,800,000
Facilities-related
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016		1,100,000
Restructuring Reserve [Roll Forward]
Balance, beginning	300,000	300,000
Additions (reductions) during the period		200,000
Payments during the period	0	(200,000)
Non-cash adjustments	(300,000)	0
Balance, ending	0	300,000
Product Rationalization
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016		129,400,000
Restructuring Reserve [Roll Forward]
Balance, beginning	0	0
Additions (reductions) during the period		56,400,000
Payments during the period	0	0
Non-cash adjustments	0	(56,400,000)
Balance, ending	$ 0	$ 0

Inventories (Schedule of Inventories) (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 101.1	$ 86.0
Work-in-process	14.7	12.6
Finished goods	321.8	319.1
Inventories, net	$ 437.6	$ 417.7

Intangible Assets (Schedule of Goodwill) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Apr. 30, 2017	Oct. 31, 2016
Goodwill [Roll Forward]
Balance, beginning	$ 2,164.7	$ 2,197.1
Net (reductions) additions during the six months ended April 30, 2017	93.7	166.0
Translation	44.3	(198.4)
Balance, ending	2,302.7	2,164.7
CooperVision
Goodwill [Roll Forward]
Balance, beginning	1,646.4	1,827.6
Net (reductions) additions during the six months ended April 30, 2017	(1.1)	9.1
Translation	43.4	(190.3)
Balance, ending	1,688.7	1,646.4
CooperSurgical
Goodwill [Roll Forward]
Balance, beginning	518.3	369.5
Net (reductions) additions during the six months ended April 30, 2017	94.8	156.9
Translation	0.9	(8.1)
Balance, ending	$ 614.0	$ 518.3

Intangible Assets (Schedule of Other Intangible Assets) (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 822.1	$ 742.9
Accumulated Amortization & Translation	337.1	301.8
Other intangible assets, net	485.0	441.1
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	40.1	36.6
Accumulated Amortization & Translation	8.4	6.8
Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	422.7	354.8
Accumulated Amortization & Translation	156.5	139.3
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	291.1	285.7
Accumulated Amortization & Translation	132.8	121.9
License and distribution rights and other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	68.2	65.8
Accumulated Amortization & Translation	$ 39.4	$ 33.8

Intangible Assets (Narrative) (Details)	6 Months Ended
Intangible Assets (Narrative) (Details)	Apr. 30, 2017 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, Impairment Loss	$ 0
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2017	66,700,000
2018	64,500,000
2019	62,100,000
2020	52,200,000
2021	$ 50,700,000

Debt (Schedule of Debt) (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Short-term:
Overdraft and other credit facilities	$ 31.3	$ 17.1
Current portion of long-term debt	11.3	210.7
Less: unamortized debt issuance cost on term loans	(1.3)	(1.5)
Short-term debt	41.3	226.3
Long-term:
Credit agreement	245.0	0.0
Term loans	1,103.8	1,111.2
Other	0.2	0.2
Less: unamortized debt issuance cost on term loans	(3.4)	(4.0)
Long-term debt	$ 1,345.6	$ 1,107.4

Debt (Narrative) (Details)				3 Months Ended		6 Months Ended	12 Months Ended
Debt (Narrative) (Details)	Mar. 01, 2016 USD ($)	Aug. 04, 2014 USD ($)	Sep. 12, 2013 USD ($)	Jul. 31, 2017 USD ($)	Apr. 30, 2017 USD ($)	Apr. 30, 2017 USD ($)	Oct. 31, 2016 USD ($)
Line of Credit Facility [Line Items]
Term loans					$ 1,103,800,000	$ 1,103,800,000	$ 1,111,200,000
Required minimum Interest coverage ratio						3.00
Required maximum total leverage ratio						3.75
Interest coverage ratio					23.95	23.95
Total leverage ratio					1.87	1.87
Amount available under the credit agreement					$ 754,800,000	$ 754,800,000
Minimum [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.125%
Maximum [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.25%
2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of credit facility, potential additional borrowing capacity	$ 750,000,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Aggregate commitment amount of credit facility	$ 1,000,000,000.0
2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of credit facility, initiation date	Mar. 01, 2016
Term loans	$ 830,000,000				830,000,000	830,000,000
Line of credit facility interest rate margin on base rate loans percentage	1.00%
Line of credit facility interest rate margin on foreign currency loans percentage	1.75%
2016 Credit Agreement [Member] \| Federal Funds Rate [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	0.00%
2016 Credit Agreement [Member] \| Eurodollar [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	0.75%
Line of Credit [Member]
Line of Credit Facility [Line Items]
Debt instrument, maturity date	Mar. 01, 2021
Term Loan $700M [Member]
Line of Credit Facility [Line Items]
Term loans		$ 700,000,000.0			0	0
Debt instrument, maturity date		Aug. 04, 2017
Debt Instrument, Issuance Date		Aug. 04, 2014
Debt term		3 years
Repayments of Debt					207,000,000		493,000,000
Term Loan $300M [Member]
Line of Credit Facility [Line Items]
Term loans			$ 300,000,000.000000		$ 285,000,000	$ 285,000,000
Debt instrument, maturity date			Sep. 12, 2018
Debt Instrument, Issuance Date			Sep. 12, 2013
Debt term			5 years
Repayments of Debt							$ 15,000,000
Amortization of term loan principal			5.00%
Debt instrument, date of first required payment			Oct. 31, 2016
Medium-term Notes [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate						0.00%
Medium-term Notes [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate						0.50%
Medium-term Notes [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate						0.75%
Medium-term Notes [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate						1.50%
Subsequent Event [Member] \| Term Loan $300M [Member]
Line of Credit Facility [Line Items]
Repayments of Debt				$ 285,000,000

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Apr. 30, 2017	Apr. 30, 2016	Nov. 01, 2016
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Effective tax rate (ETR)	4.70%	5.40%
Unrecognized tax benefits			$ 39.9
Unrecognized tax benefits that would impact ETR			29.7
Interest and penalties			3.7
Unrecognized tax benefits related to tax positions			$ 1.6

Earnings Per Share (Schedule of Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Earnings Per Share [Abstract]
Net income attributable to Cooper stockholders	$ 104,900	$ 74,100	$ 180,700	$ 125,500
Basic:
Weighted average common shares	48,959	48,400	48,900	48,400
Basic earnings per common share attributable to Cooper stockholders	$ 2.14	$ 1.53	$ 3.70	$ 2.59
Diluted:
Effect of potential dilutive common shares	500	500	600	400
Diluted weighted average common shares	49,499	48,853	49,500	48,800
Diluted earnings per common share attributable to Cooper stockholders	$ 2.12	$ 1.52	$ 3.65	$ 2.57

Earnings Per Share (Schedule of Stock Options to Purchase Common Stock Not Included in Diluted Net Income Per Share Calculation) (Details) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Numbers of stock option shares excluded	192	537	234	537
Range of exercise prices, lower limit	$ 175.31	$ 131.6	$ 162.28	$ 131.6
Range of exercise prices, upper limit	$ 175.31	$ 162.69	$ 175.31	$ 162.69
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Numbers of stock option shares excluded	1	7	1	2

Share-Based Compensation Plans (Schedule Of Compensation Expense And Related Income Tax Benefit For Share-Based Awards) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 8.7	$ 7.9	$ 19.8	$ 14.6
Related income tax benefit	2.6	2.3	5.9	4.3
Selling, general and administrative expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	7.6	7.0	17.2	12.8
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	0.8	0.7	2.0	1.2
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	0.3	0.2	0.6	0.6
Capitalized in inventory [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 0.8	$ 0.7	$ 2.0	$ 1.2

Stockholders' Equity (Schedule of Changes in Accumulated Other Comprehensive Income (Loss))(Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Apr. 30, 2017	Oct. 31, 2016
Foreign Currency Translation Adjustment [Roll Forward]
Foreign Currency Translation Adjustment, Beginning Balance	$ (461.4)	$ (171.8)
Foreign Currency Translation Adjustment, Gross change in value for the period	66.5	(289.6)
Foreign Currency Translation Adjustment, Tax effect for the period		0.0
Foreign Currency Translation Adjustment, Ending Balance	(394.9)	(461.4)
Minimum Pension Liability [Roll Forward]
Minimum Pension Liability, Beginning Balance	(28.2)	(19.8)
Minimum Pension Liability, Gross change in value for the period	0.0	(13.7)
Minimum Pension Liability, Tax effect for the period		5.3
Minimum Pension Liability, Ending Balance	(28.2)	(28.2)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Total, Beginning balance	(489.6)	(191.6)
Gross change in value for the period	66.5	(303.3)
Tax effect for the period		5.3
Total, Ending balance	$ (423.1)	$ (489.6)

Stockholders' Equity (Share Repurchases) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	6 Months Ended
	Apr. 30, 2017	Apr. 30, 2017	Apr. 30, 2016	Mar. 21, 2017	Dec. 15, 2011
Equity [Abstract]
Share Repurchase Program, maximum amount authorized				$ 1,000.0	$ 500.0
Number of common stock repurchased, shares	150,000	150,000	0
Treasury Stock, Value, Acquired, Cost Method	$ 29.5
Accelerated Share Repurchases, Final Price Paid Per Share	$ 196.82
Share Repurchase Program, remaining authorized amount	$ 589.0	$ 589.0

Stockholders' Equity (Dividends) (Details) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Feb. 09, 2017	Apr. 30, 2017	Apr. 30, 2016
Equity [Abstract]
Dividends on common stock	$ 1.5	$ 1.5	$ 1.5
Cash dividend, per share	$ 0.03
Dividends payable, date of record		Jan. 23, 2017

Employee Benefits (Schedule of Components of Net Periodic Pension Costs) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Service cost	$ 2.5	$ 2.3	$ 5.0	$ 4.6
Interest cost	1.1	1.2	2.2	2.5
Expected return on plan assets	(1.8)	(1.6)	(3.6)	(3.3)
Recognized net actuarial loss	0.7	0.4	1.4	0.8
Net periodic pension cost	$ 2.5	$ 2.3	$ 5.0	$ 4.6

Employee Benefits (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Company's contribution to the pension plan	$ 2.5	$ 2.5
Defined benefit plan, estimated future employer contributions in current fiscal year	$ 7.5
Expected rate of return on plan assets for determining net periodic pension cost	8.00%

Contingencies (Details)	26 Months Ended
Contingencies (Details)	Apr. 30, 2017 action
Commitments and Contingencies Disclosure [Abstract]
Number of putative class action complaints filed (over)	50

Business Segment Information (Schedule of Segment Information) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Segment Reporting Information [Line Items]
Net sales	$ 522,400	$ 483,800	$ 1,021,500	$ 933,400
Operating income (loss)	117,100	89,800	207,800	147,200
Interest expense	7,700	7,600	15,000	12,900
Other (income) expense, net	(100)	(400)	3,200	900
Income before income taxes	109,500	82,600	189,600	133,400
CooperVision
Segment Reporting Information [Line Items]
Net sales	408,500	391,200	797,800	755,600
Operating income (loss)	112,100	83,600	199,400	136,400
CooperSurgical
Segment Reporting Information [Line Items]
Net sales	113,900	92,600	223,700	177,800
Operating income (loss)	16,800	17,700	33,300	33,100
Corporate
Segment Reporting Information [Line Items]
Operating income (loss)	(11,800)	(11,500)	(24,900)	(22,300)
Toric lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	131,800	120,500	252,500	228,000
Multifocal lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	42,900	42,500	85,300	82,900
Single-use sphere lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	104,100	97,600	203,700	188,400
Non single-use sphere and other \| CooperVision
Segment Reporting Information [Line Items]
Net sales	$ 129,700	$ 130,600	$ 256,300	$ 256,300

Business Segment Information (Schedule of Identifiable Assets By Segment Information) (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 4,749.8	$ 4,478.6
CooperVision
Segment Reporting Information [Line Items]
Total Identifiable assets	3,454.0	3,382.4
CooperSurgical
Segment Reporting Information [Line Items]
Total Identifiable assets	1,086.4	907.1
Corporate
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 209.4	$ 189.1

Business Segment Information (Schedule of Net Sales To External Customers By Country Of Domicile) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 522,400	$ 483,800	$ 1,021,500	$ 933,400
United States
Segment Reporting Information [Line Items]
Total net sales to external customers	235,300	221,400	459,500	428,200
Europe
Segment Reporting Information [Line Items]
Total net sales to external customers	175,600	165,900	343,900	323,000
Rest of world
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 111,500	$ 96,500	$ 218,100	$ 182,200

Business Segment Information (Schedule of Long-Lived Assets By Country Of Domicile) (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Segment Reporting Information [Line Items]
Total long-lived assets	$ 886.5	$ 877.7
United States
Segment Reporting Information [Line Items]
Total long-lived assets	463.4	464.1
Europe
Segment Reporting Information [Line Items]
Total long-lived assets	342.2	334.4
Rest of world
Segment Reporting Information [Line Items]
Total long-lived assets	$ 80.9	$ 79.2